Scientists have long known that the blood carries a wealth of information about human health, but most studies have examined proteins and metabolites in isolation, capturing snapshots rather than the slow-motion film of biology unfolding over years. A new study published in Genome Medicine has now delivered one of the most systematic long-term maps to date of how the blood proteome and the blood metabolite influence one another, and how those relationships shape metabolic health. Drawing on more than a decade of repeated measurements from a population-based Chinese cohort, the research identifies dozens of prospective protein-metabolite pairings and traces their connections to type 2 diabetes, metabolic syndrome, hypertension, and obesity.
The work, led by Kui Deng, Yu-ming Chen, and colleagues at Sun Yat-sen University together with collaborators at the Human Metabolomics Institute, Westlake University-affiliated Hangzhou First People’s Hospital, Shanghai Jiao Tong University School of Medicine, and Ningbo University, is described by its authors as the first population-based study to systematically investigate longitudinal, prospective associations between serum proteins and serum metabolites. Rather than measuring both molecular layers at a single time point, the team followed participants across multiple clinic visits, allowing them to ask whether the level of a circulating protein at one visit predicted the level of a metabolite at a later one, a design that strengthens the case for directional, temporal relationships rather than mere correlation.
The foundation of the analysis is the Guangzhou Nutrition and Health Study, an ongoing population cohort of middle-aged and elderly adults. For this investigation, the researchers assembled data from 485 participants with an average age of 56.9 years, plus or minus about 4.5 years. Serum proteome measurements, covering 411 proteins, were available at three cohort visits, yielding 1,455 protein profiles in total. Serum metabolome measurements, covering 196 metabolites, were collected at four visits spread across 12.3 years of follow-up, producing 1,940 metabolite profiles. This repeated-measures architecture is what distinguishes the study from earlier cross-sectional surveys: each participant serves, in effect, as their own temporal control, and the passage of time between visits becomes an explicit part of the statistical model.
Methodologically, the team divided participants into a discovery set of 402 individuals and a validation set of 83, a split designed to guard against spurious findings. To interrogate every possible protein-metabolite combination, they applied linear mixed-effects models, a statistical framework well suited to longitudinal data because it can accommodate the nested structure of repeated measurements within individuals while adjusting for within-person correlation. Each pairwise protein-metabolite combination was tested for a prospective association, in which protein levels measured at one visit were related to metabolite levels measured subsequently. Given the enormous number of tests inherent in such a pairwise mapping, the researchers controlled the false discovery rate, a standard safeguard in high-dimensional omics research that limits the expected proportion of false positives among declared discoveries.
Out of this systematic screen emerged 53 longitudinal prospective associations linking 28 proteins to 34 metabolites. These pairs constitute what the investigators call protein-metabolite axes: recurring, temporally ordered relationships in which circulating proteins appear to anticipate changes in the small-molecule chemical traffic of the blood. The identity of the linked molecules spans well-known metabolic territory, and the fact that the associations were confirmed in a held-out validation subset lends weight to their robustness. Because metabolites are often the downstream products or substrates of protein-driven enzymatic activity, such axes plausibly represent readable signatures of physiological regulation in action.
But mapping the axes was only the first step. The researchers then asked whether the proteins and metabolites involved were themselves connected to metabolic outcomes. They examined 13 metabolic traits, including standard clinical measures such as body mass index, waist circumference, waist-to-hip ratio, systolic and diastolic blood pressure, glycated hemoglobin A1c, Homeostatic Model Assessment for Insulin Resistance, total cholesterol, high-density and low-density lipoprotein cholesterol, and triglycerides. They also examined four metabolic diseases: type 2 diabetes, metabolic syndrome, hypertension, and obesity. Using linear mixed-effects models for the traits and logistic regression for the disease outcomes, the team uncovered a dense web of associations: 91 links between proteins and metabolic traits, 44 between proteins and metabolic diseases, 104 between metabolites and metabolic traits, and 7 between metabolites and metabolic diseases.
The most consequential findings came from stitching these layers together. Through mediation analysis, a statistical technique that tests whether a third variable explains the pathway between an exposure and an outcome, the researchers identified 17 protein-metabolite-metabolic trait or disease pathways. In these pathways, a circulating protein is prospectively associated with a metabolite, and that metabolite in turn carries the association forward to a clinical trait or disease. Such chains suggest a mechanistic logic: a protein influences a small-molecule mediator, which then contributes to disordered metabolism. If validated in independent populations and experiments, these axes could point to intervention targets, since metabolites lying on a causal path between a protein and a disease represent a potential point where the chain could be interrupted.
The four diseases under study are among the most burdensome chronic conditions worldwide, and all four are tightly intertwined with lipid and glucose metabolism. Type 2 diabetes, characterized by progressive insulin resistance and dysregulated glycemic control, metabolic syndrome, a cluster of central obesity, elevated blood pressure, and abnormal blood lipids, hypertension, and obesity together account for an enormous share of cardiovascular and renal morbidity. By anchoring molecular associations to these clinically meaningful endpoints, the study moves beyond cataloging molecular correlations and speaks directly to the biology of disease risk. The inclusion of insulin resistance measures such as HOMA-IR alongside conventional lipid panels reflects an attempt to capture metabolic dysfunction in its several dimensions rather than relying on any single marker.
The researchers are careful to frame the identified axes as potential rather than proven intervention targets. Longitudinal prospective association, even with mediation evidence, does not by itself establish causation, and the observed pathways could reflect confounding by diet, medication use, inflammation, or organ function that neither proteins nor metabolites fully capture. The cohort, while well characterized, consists of middle-aged and elderly Chinese adults, and the generalizability of specific protein-metabolite pairings to other populations and age groups will require replication. The authors note that the work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, the Key Research and Development Program of Guangzhou, and the 5010 Program for Clinical Researches of Sun Yat-sen University, and they acknowledge the participants of the Guangzhou Nutrition and Health Study as well as the university’s high-performance computing platform.
Even with those caveats, the significance of the resource is considerable. Population-scale efforts in genomics have flourished in part because DNA is stable and easy to measure repeatedly; the proteome and metabolome are far more dynamic, sensitive to fasting state, circadian rhythm, and recent meals, which makes long-term longitudinal mapping technically and logistically demanding. By demonstrating that such mapping is feasible at population scale, and by releasing a catalog of temporally ordered protein-metabolite associations linked to metabolic outcomes, the study provides a scaffold that other researchers can build upon, whether through Mendelian randomization, experimental perturbation in cell and animal models, or integration with genetic and gut microbiome data. The authors suggest that the protein-metabolite axes they describe may serve as potential targets for intervention to enhance metabolic health, and the 17 pathways they delineated offer a concrete starting point for that longer scientific agenda, one in which the slow molecular conversations conducted in the bloodstream are finally being transcribed and translated into clinical insight.
Subject of Research: Longitudinal mapping of serum protein-metabolite associations and their role in metabolic health
Article Title: Longitudinal mapping of the blood proteome to blood metabolome reveals the role of the protein-metabolite axes in metabolic health
Article References: Deng, K., Zhou, K., Xiao, C., Lu, Z., Ru, D., Wang, X., Xi, Y., Jia, S., Huang, F., Chen, T., Zheng, J.-S., Xie, G., & Chen, Y.-M. (2026). Longitudinal mapping of the blood proteome to blood metabolome reveals the role of the protein-metabolite axes in metabolic health. Genome Medicine. https://doi.org/10.1186/s13073-026-01775-y
Image Credits: AI Generated
DOI: 10.1186/s13073-026-01775-y
Keywords: proteome, metabolome, metabolic health, type 2 diabetes, metabolic syndrome, hypertension, obesity, longitudinal cohort, linear mixed-effects model, protein-metabolite axes, biomarkers, metabolomics
Cite Scienmag News
APA MLA Chicago
Daisy Hatcher. (September 20, 2026). Blood Proteins and Metabolites Tracked Over a Decade Reveal New Drivers of Metabolic Health. Scienmag. https://scienmag.com/blood-proteins-and-metabolites-tracked-over-a-decade-reveal-new-drivers-of-metabolic-health/
Daisy Hatcher. “Blood Proteins and Metabolites Tracked Over a Decade Reveal New Drivers of Metabolic Health.” Scienmag, 20 September 2026, https://scienmag.com/blood-proteins-and-metabolites-tracked-over-a-decade-reveal-new-drivers-of-metabolic-health/. Accessed 20 September 2026.
Daisy Hatcher. “Blood Proteins and Metabolites Tracked Over a Decade Reveal New Drivers of Metabolic Health.” Scienmag. September 20, 2026. https://scienmag.com/blood-proteins-and-metabolites-tracked-over-a-decade-reveal-new-drivers-of-metabolic-health/
Copy citation Download RIS
Tags: Biomarkersblood metabolitesblood proteinshypertensionlinear mixed-effects modellong-term health monitoringlongitudinal cohortlongitudinal metabolic health studymetabolic disease driversmetabolic healthmetabolic syndromemetabolic syndrome biomarkersmetabolomeMetabolomicsobesityobesity and hypertension molecular markerspopulation-based Chinese cohortprospective biomarker discoveryprotein-metabolite axesproteomeproteome-metabolite interactionsserum proteomics and metabolomicsType 2 diabetestype 2 diabetes predictors
